ZORYVE (roflumilast) topical cream 0.15%
Once-daily & steroid-free, for patients down to 6 years old

ITCH RELIEF

ITCH IMPROVEMENT AT WEEK 4 WITH RESULTS OBSERVED WITHIN 24 HOURS

Symptoms illustrated. Not an actual patient.

TWICE AS MANY PATIENTS ACHIEVED ITCH IMPROVEMENT AT WEEK 4 WITH ZORYVE3

2Xas many patients achieved WI-NRS Success at Week 4 with ZORYVE (32%; n=542) vs with vehicle (17%; n=271), P<0.0001, nominal3*

Secondary endpoint

Greater itch improvement observed within 24 HOURS after first application with ZORYVE as compared to vehicle3*

Greater itch improvement through Week 4 with results observed within 24 hours with ZORYVETreatment DayZORYVE maintained consistently greater itch relief vs vehicle through Week 4ZORYVE (n=884)Vehicle (n=453)211471280.0-1.0-2.0-3.0CHANGE IN WI-NRS FROM BASELINEP<0.0001 for all time points, nominal.
Greater itch improvement through Week 4 with results observed within 24 hours with ZORYVEZORYVE maintained consistently greater itch relief vs vehicle through Week 40.0–1.0–2.0–3.0Treatment DayZORYVE (n=884)Vehicle (n=453)CHANGE IN WI-NRS FROM BASELINEP<0.0001 for all time points, nominal. 71142128

*Data are pooled analyses of the INTEGUMENT 1 & 2 studies.

Daily WI-NRS was a prespecified exploratory endpoint. Patients were asked to keep a daily diary logging itch symptoms and their severity. Day 1 represents baseline, first application. Evaluated in all patients, not just those with baseline WI-NRS score ≥4. Pooled analysis P-values are nominal.

WI-NRS Success defined as ≥4-point improvement for patients with a baseline score ≥4. WI-NRS scale: 0 (no itch) to 10 (worst imaginable itch).

WI-NRS = Worst Itch Numeric Rating Scale.

BASELINE

vIGA-AD = 3

Baseline photo of a clinical trial patient’s wrist before treatment and Week 4 photo of a clinical trial patient’s wrist on ZORYVE

WEEK 4

vIGA-AD = 0

Actual clinical trial patient